Research Analysts Issue Forecasts for BCRX Q4 Earnings

Key Points

• HC Wainwright raised its Q4 2026 EPS forecast for BioCryst Pharmaceuticals to $0.18 from $0.14, maintaining a “Buy” rating and $32 price target.
• Analyst sentiment remains favorable, with eight Buy ratings and four Holds; the stock has a “Moderate Buy” consensus rating and an average price target of $20.60.
• BioCryst exceeded its latest quarterly expectations, reporting EPS of $0.30 versus $0.15 expected and revenue of $218.25 million, up 33.6% year over year.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Investment analysts at HC Wainwright boosted their Q4 2026 earnings per share (EPS) estimates for BioCryst Pharmaceuticals in a note issued to investors on Thursday, August 6th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will earn $0.18 per share for the quarter, up from their previous forecast of $0.14. HC Wainwright currently has a "Buy" rating and a $32.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($2.44) per share.

Other research analysts have also issued reports about the stock. Wall Street Zen raised shares of BioCryst Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Needham & Company LLC cut their target price on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a "buy" rating on the stock in a research note on Wednesday, May 6th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. JPMorgan Chase & Co. assumed coverage on BioCryst Pharmaceuticals in a report on Monday, July 13th. They issued a "neutral" rating and a $12.00 target price for the company. Finally, Cantor Fitzgerald increased their price target on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an "overweight" rating in a research report on Tuesday, June 30th. Eight analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $20.60.

BioCryst Pharmaceuticals Price Performance

BCRX opened at $9.81 on Friday. BioCryst Pharmaceuticals has a 1 year low of $6.00 and a 1 year high of $11.22. The company has a market capitalization of $2.51 billion, a price-to-earnings ratio of -6.54 and a beta of 0.55. The firm's fifty day moving average price is $9.47 and its two-hundred day moving average price is $8.82.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.15. The company had revenue of $218.25 million for the quarter, compared to analysts' expectations of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.BioCryst Pharmaceuticals's quarterly revenue was up 33.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.15 earnings per share.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Visionary Wealth Advisors purchased a new stake in shares of BioCryst Pharmaceuticals during the 2nd quarter worth approximately $169,000. Sanctuary Advisors LLC bought a new position in BioCryst Pharmaceuticals during the second quarter valued at $587,000. Elevation Point Wealth Partners LLC purchased a new stake in BioCryst Pharmaceuticals in the second quarter worth $126,000. Commerce Bank bought a new stake in shares of BioCryst Pharmaceuticals in the second quarter valued at $383,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter valued at $103,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source